Annual EBITDA
-$360.39 M
-$69.47 M-23.88%
December 31, 2023
Summary
- As of February 12, 2025, MDGL annual EBITDA is -$360.39 million, with the most recent change of -$69.47 million (-23.88%) on December 31, 2023.
- During the last 3 years, MDGL annual EBITDA has fallen by -$154.19 million (-74.78%).
- MDGL annual EBITDA is now -534.19% below its all-time high of $83.00 million, reached on December 31, 2009.
Performance
MDGL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$102.99 M
+$45.06 M+30.44%
September 30, 2024
Summary
- As of February 12, 2025, MDGL quarterly EBITDA is -$102.99 million, with the most recent change of +$45.06 million (+30.44%) on September 30, 2024.
- Over the past year, MDGL quarterly EBITDA has increased by +$45.06 million (+30.44%).
- MDGL quarterly EBITDA is now -186.71% below its all-time high of $118.78 million, reached on September 30, 2009.
Performance
MDGL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$502.65 M
-$7.89 M-1.59%
September 30, 2024
Summary
- As of February 12, 2025, MDGL TTM EBITDA is -$502.65 million, with the most recent change of -$7.89 million (-1.59%) on September 30, 2024.
- Over the past year, MDGL TTM EBITDA has dropped by -$7.89 million (-1.59%).
- MDGL TTM EBITDA is now -624.87% below its all-time high of $95.77 million, reached on March 31, 2010.
Performance
MDGL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MDGL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.9% | +30.4% | -1.6% |
| 3 y3 years | -74.8% | +30.4% | -1.6% |
| 5 y5 years | -788.0% | +30.4% | -1.6% |
MDGL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -49.3% | at low | -79.4% | +30.4% | -107.8% | at low |
| 5 y | 5-year | -279.9% | at low | -244.1% | +30.4% | -429.9% | at low |
| alltime | all time | -534.2% | at low | -186.7% | +30.4% | -624.9% | at low |
Madrigal Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$102.99 M(-30.4%) | -$502.65 M(+1.6%) |
| Jun 2024 | - | -$148.05 M(+3.1%) | -$494.76 M(+15.2%) |
| Mar 2024 | - | -$143.53 M(+32.8%) | -$429.49 M(+19.2%) |
| Dec 2023 | -$360.39 M(+23.9%) | -$108.08 M(+13.6%) | -$360.39 M(+7.1%) |
| Sep 2023 | - | -$95.10 M(+14.9%) | -$336.40 M(+4.8%) |
| Jun 2023 | - | -$82.77 M(+11.2%) | -$320.88 M(+4.2%) |
| Mar 2023 | - | -$74.44 M(-11.5%) | -$307.94 M(+5.9%) |
| Dec 2022 | -$290.92 M(+20.5%) | -$84.09 M(+5.7%) | -$290.92 M(+7.2%) |
| Sep 2022 | - | -$79.57 M(+13.9%) | -$271.27 M(+6.5%) |
| Jun 2022 | - | -$69.84 M(+21.6%) | -$254.70 M(+3.4%) |
| Mar 2022 | - | -$57.41 M(-10.9%) | -$246.42 M(+1.9%) |
| Dec 2021 | -$241.44 M(+17.1%) | -$64.44 M(+2.3%) | -$241.87 M(+2.1%) |
| Sep 2021 | - | -$63.00 M(+2.3%) | -$236.87 M(+1.9%) |
| Jun 2021 | - | -$61.56 M(+16.4%) | -$232.54 M(+5.1%) |
| Mar 2021 | - | -$52.87 M(-11.1%) | -$221.19 M(+7.3%) |
| Dec 2020 | -$206.20 M(+117.4%) | -$59.44 M(+1.3%) | -$206.20 M(+16.7%) |
| Sep 2020 | - | -$58.67 M(+16.8%) | -$176.69 M(+24.3%) |
| Jun 2020 | - | -$50.21 M(+32.6%) | -$142.19 M(+24.0%) |
| Mar 2020 | - | -$37.88 M(+26.6%) | -$114.65 M(+20.9%) |
| Dec 2019 | -$94.86 M(+133.7%) | -$29.93 M(+23.8%) | -$94.86 M(+19.5%) |
| Sep 2019 | - | -$24.17 M(+6.6%) | -$79.36 M(+19.3%) |
| Jun 2019 | - | -$22.68 M(+25.3%) | -$66.50 M(+28.8%) |
| Mar 2019 | - | -$18.09 M(+25.4%) | -$51.63 M(+27.2%) |
| Dec 2018 | -$40.59 M(+26.9%) | -$14.43 M(+27.6%) | -$40.59 M(+15.9%) |
| Sep 2018 | - | -$11.31 M(+45.0%) | -$35.01 M(+8.3%) |
| Jun 2018 | - | -$7.80 M(+10.7%) | -$32.33 M(-1.9%) |
| Mar 2018 | - | -$7.05 M(-20.4%) | -$32.96 M(+3.0%) |
| Dec 2017 | -$31.98 M(+27.1%) | -$8.85 M(+2.6%) | -$31.98 M(+3.6%) |
| Sep 2017 | - | -$8.63 M(+2.3%) | -$30.88 M(-14.9%) |
| Jun 2017 | - | -$8.43 M(+38.8%) | -$36.30 M(+19.0%) |
| Mar 2017 | - | -$6.08 M(-21.6%) | -$30.51 M(+21.2%) |
| Dec 2016 | -$25.18 M(+678.7%) | -$7.75 M(-44.8%) | -$25.18 M(+37.2%) |
| Sep 2016 | - | -$14.05 M(+432.4%) | -$18.34 M(+254.5%) |
| Jun 2016 | - | -$2.64 M(+257.6%) | -$5.18 M(-76.3%) |
| Mar 2016 | - | -$738.00 K(-19.6%) | -$21.87 M(-47.0%) |
| Dec 2015 | -$3.23 M(-96.1%) | -$918.40 K(+4.4%) | -$41.30 M(-31.3%) |
| Sep 2015 | - | -$880.00 K(-95.4%) | -$60.10 M(-23.4%) |
| Jun 2015 | - | -$19.34 M(-4.1%) | -$78.51 M(-2.7%) |
| Mar 2015 | - | -$20.16 M(+2.2%) | -$80.70 M(-3.1%) |
| Dec 2014 | -$83.28 M | -$19.73 M(+2.3%) | -$83.28 M(-4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | - | -$19.28 M(-10.4%) | -$86.85 M(-2.6%) |
| Jun 2014 | - | -$21.53 M(-5.3%) | -$89.22 M(-0.5%) |
| Mar 2014 | - | -$22.74 M(-2.4%) | -$89.62 M(+3.0%) |
| Dec 2013 | -$87.04 M(+44.6%) | -$23.30 M(+7.6%) | -$87.04 M(+7.0%) |
| Sep 2013 | - | -$21.65 M(-1.3%) | -$81.33 M(+9.8%) |
| Jun 2013 | - | -$21.94 M(+8.8%) | -$74.05 M(+12.2%) |
| Mar 2013 | - | -$20.16 M(+14.6%) | -$66.03 M(+9.7%) |
| Dec 2012 | -$60.20 M(+36.9%) | -$17.59 M(+22.4%) | -$60.20 M(+14.5%) |
| Sep 2012 | - | -$14.37 M(+3.3%) | -$52.56 M(+5.0%) |
| Jun 2012 | - | -$13.91 M(-3.0%) | -$50.06 M(+4.8%) |
| Mar 2012 | - | -$14.34 M(+44.1%) | -$47.78 M(+8.7%) |
| Dec 2011 | -$43.97 M(+25.7%) | -$9.95 M(-16.2%) | -$43.97 M(+4.9%) |
| Sep 2011 | - | -$11.87 M(+2.1%) | -$41.92 M(+5.3%) |
| Jun 2011 | - | -$11.63 M(+10.4%) | -$39.81 M(+8.3%) |
| Mar 2011 | - | -$10.53 M(+33.2%) | -$36.75 M(+5.1%) |
| Dec 2010 | -$34.97 M(-142.1%) | -$7.90 M(-19.0%) | -$34.97 M(+4.3%) |
| Sep 2010 | - | -$9.76 M(+14.0%) | -$33.53 M(-135.3%) |
| Jun 2010 | - | -$8.56 M(-2.1%) | $95.01 M(-0.8%) |
| Mar 2010 | - | -$8.74 M(+35.2%) | $95.77 M(+15.4%) |
| Dec 2009 | $83.00 M(-191.2%) | -$6.46 M(-105.4%) | $83.00 M(+29.1%) |
| Sep 2009 | - | $118.78 M(-1622.4%) | $64.28 M(-180.1%) |
| Jun 2009 | - | -$7.80 M(-63.7%) | -$80.21 M(-15.3%) |
| Mar 2009 | - | -$21.51 M(-14.6%) | -$94.73 M(+4.1%) |
| Dec 2008 | -$90.99 M(+44.7%) | -$25.18 M(-2.1%) | -$90.99 M(+12.0%) |
| Sep 2008 | - | -$25.72 M(+15.2%) | -$81.27 M(+15.9%) |
| Jun 2008 | - | -$22.32 M(+25.6%) | -$70.12 M(+8.9%) |
| Mar 2008 | - | -$17.77 M(+14.9%) | -$64.42 M(+2.5%) |
| Dec 2007 | -$62.87 M(+13.3%) | -$15.46 M(+6.2%) | -$62.86 M(+5.5%) |
| Sep 2007 | - | -$14.57 M(-12.3%) | -$59.58 M(-0.0%) |
| Jun 2007 | - | -$16.62 M(+2.5%) | -$59.59 M(+38.7%) |
| Mar 2007 | - | -$16.21 M(+33.1%) | -$42.97 M(+60.6%) |
| Dec 2006 | -$55.50 M(-19.2%) | -$12.18 M(-16.5%) | -$26.75 M(+83.5%) |
| Sep 2006 | - | -$14.58 M(-19.3%) | -$14.58 M(-19.3%) |
| Dec 2005 | -$68.72 M(+56.9%) | - | - |
| Mar 2005 | - | -$18.07 M(+231.4%) | -$18.07 M(+231.4%) |
| Dec 2004 | -$43.80 M(+60.5%) | - | - |
| Mar 2004 | - | -$5.45 M | -$5.45 M |
| Dec 2003 | -$27.29 M(+274.2%) | - | - |
| Dec 2002 | -$7.29 M(+1718.5%) | - | - |
| Dec 2001 | -$401.00 K | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual EBITDA year-on-year change?
- What is Madrigal Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Madrigal Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM EBITDA year-on-year change?
What is Madrigal Pharmaceuticals annual EBITDA?
The current annual EBITDA of MDGL is -$360.39 M
What is the all time high annual EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual EBITDA is $83.00 M
What is Madrigal Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, MDGL annual EBITDA has changed by -$69.47 M (-23.88%)
What is Madrigal Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of MDGL is -$102.99 M
What is the all time high quarterly EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly EBITDA is $118.78 M
What is Madrigal Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, MDGL quarterly EBITDA has changed by +$45.06 M (+30.44%)
What is Madrigal Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of MDGL is -$502.65 M
What is the all time high TTM EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM EBITDA is $95.77 M
What is Madrigal Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, MDGL TTM EBITDA has changed by -$7.89 M (-1.59%)